TILDRAKIZUMAB

The PBAC recommended tildrakizumab 200 mg (100 mg/mL injection, 2 x 1 mL syringe) for the treatment of severe chronic plaque psoriasis. The PBAC considered that tildrakizumab 200 mg would result in the same outcomes (i.e. efficacy and safety) compared with tildrakizumab 100 mg. The PBAC noted and welcomed input from the Australasian College of Dermatologists, who advocated for increasing the maintenance dose to 200 mg to provide an opportunity to improve outcomes in patient with severe disease or obesity. The PBAC considered that treating doctors, at their discretion, may escalate the dose of tildrakizumab to 200 mg in any patient who has responded adequately to the most recent course of tildrakizumab 100 mg, noting that the magnitude of any improved outcomes may be modest.